Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/50—Nitrogen atoms bound to hetero atoms
  • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention is directed to benzenesulfonamide compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating sodium channel-mediated diseases or conditions, such as epilepsy and/or epileptic seizure disorder, as well as other diseases and conditions associated with the mediation of sodium channels.
• sodium channel-mediated diseases or conditions such as epilepsy and/or epileptic seizure disorder, as well as other diseases and conditions associated with the mediation of sodium channels.
• Voltage gated sodium channels are critical determinants of cellular excitability in muscle and nerve (Hille, B, Ion Channels of Excitable Membranes (2001), Sunderland, MA, Sinauer Associates, Inc.). Four isoforms in particular, Na 1.1 ,
• Na ⁇ l .2, Na ⁇ l .3, and Na 1.6 account for the majority of sodium current in the neurons of the central nervous system.
• Na 1.3 is primarily expressed embryonically. Beyond the neonatal stage, Na 1.1 , Na 1.2, and Na ⁇ l .6 are the critical isoforms that regulate neuronal signaling in the brain (Catterall, W.A., Annual Review of Pharmacology and Toxicology (2014), Vol. 54, pp. 317-338).
• Na 1.5 is expressed mainly in cardiac myocytes (Raymond, C.K. et ai, J. Biol. Chem. (2004), Vol. 279, No. 44, pp. 46234-41), including atria, ventricles, the sino atrial node, atrio-ventricular node and cardiac Purkinje fibers. Mutations in human Na 1.5 result in multiple arrhythmic syndromes, including, for example, long QT3 (LQT3), Brugada syndrome (BS), an inherited cardiac conduction defect, sudden unexpected nocturnal death syndrome (SUNDS) and sudden infant death syndrome (SIDS) (Liu, H., et ai, Am. J. Pharmacogenomics (2003), Vol. 3, No. 3, pp. 173-9). Sodium channel blocker therapy has been used extensively in treating cardiac arrhythmias.
• LQT3 long QT3
• BS Brugada syndrome
• SUNDS sudden unexpected nocturnal death syndrome
• SIDS sudden infant
• Epilepsy is a condition characterized by excessive synchronous excitability in the brain that arises when the delicate balance of excitatory and inhibitory signals in the brain fall out of equilibrium. This can happen either due to an excess of excitation, or a deficiency of inhibition. Mutations in the genes encoding Na ⁇ channels have been linked to both types of disequilibrium.
• Na 1.1 has been identified as the primary Na ⁇ isoform of inhibitory interneurons (Yu, F.H. et al., Nat. Neurosci. (2006), Vol. 9, pp. 1142-1149). These interneurons synapse on many other neurons, including excitatory glutamatergic neurons. Action potentials in the interneurons induce the release of the neurotransmitter GABA onto other neurons, hyperpolarizing them and thus dampening excitation. This results in a negative feedback that enables controlled signaling and prevents local signals from expanding into waves of excitation that spread across large brain regions. Because of this critical role in inhibitory interneurons, mutations that impair Na 1.1 channel function can lead to a failure of those neurons to activate and release GABA (Ogiwara, I.
• SCN1A Mutations in the gene encoding Na 1.1 (SCN1A) fall into two broad classes, those that cause generalized epilepsy with febrile seizures plus (GEFS+) and those that cause severe myoclonic epilepsy of infancy (SMEI), also known as Dravet Syndrome or early infantile epileptic encephalopathy 6 (EIEE6) (McKusik, V.K. et al., A Epileptic Encephalopathy, Early Infantile 6, EIEE6 (2012), Online Mendelian
• SMEI mutations are heterozygous autosomal dominant mutations and are often caused by a gene deletion or truncation that leads to a channel with little or no function.
• the mutations arise de novo, or in a few cases have been shown to arise in asymptomatic mosaic parents (Tuncer, F.N. et al., Epilepsy Research (2015), Vol. 113, pp. 5-10).
• Patients are born phenotypically normal and meet developmental milestones until the onset of seizures, typically between the age of 6 months and 1 year. This time of onset is believed to be a consequence of the normal decrease in the expression of the embryonic isoform Na 1.3 and the coincident rise of Na 1.1.
• Dravet syndrome patients 80 to 85% of phenotypically diagnosed Dravet syndrome patients are believed to have a responsible mutation in SCN1A, while the other 15-20% of patients have other mutations or are of unknown etiology.
• SCN1A epilepsy
• GEFS+ is often caused by missense SCN1A mutations that induce relatively mild channel dysfunction, consistent with the relatively milder seizure phenotype.
• a large and growing number of mutations have been identified, and both the severity and the penetrance of the phenotype varies considerably.
• mice have been developed that harbor the same mutations identified in SMEI and GEFS+ patients. In both cases the mice replicate the human phenotype well, though the penetrance of the phenotype can be significantly impacted by the genetic background. Some mouse strains tolerate the mutations relatively well, while in other strains the same mutations can cause drastic seizure phenotypes.
• AIS action initial segment
• Na 1.6 tends to be especially densely localized the early AIS (distal from the soma) where it is thought to act to trigger action potential initiation.
• Na 1.2 is more highly localized to the segment of the AIS most proximal to the soma. Mutations in both SCN2A (Na 1.2) and SCN8A (Na 1.6) have been linked to epilepsy and cognitive delay. The effects of the mutations are diverse both at the level of the impact on channel function, and on the patient phenotype. Both Na 1.2 and Na 1.6 are also expressed in peripheral neurons. Na 1.6 is especially dense at the nodes of Ranvier of myelinated neurons, where it is critical for maintaining salutatory conduction and high speed neuronal signaling.
• the epilepsy mutations are presumed to be primarily gain of function mutations, meaning that they lead to an increase in the amount of sodium current and thereby increasing excitability. Establishing the impact on channel function in vivo beyond reasonable doubt is challenging and some of these mutations may yet lead to loss of function phenotypes.
• Mutations in SCN8A have likewise been reported to show a range of gain and loss of function effects on the Na 1.6 channel though, for Na 1.6, most mutations examined have been associated with gain of function phenotypes. Mutations in Na 1.6 have been linked with epilepsy and autism spectrum disorders (Trudeau, M.M. et al., Journal of Medical Genetics (2006), Vol. 43, pp. 527-530; Veeramah, K.R. et al., Am. J. Hum. Genet. (2012), Vol. 90, pp. 502-510; Vaher, U. et ai, Journal of Child
• EIEE13 early infantile epileptic encephalopathy
• phenytoin does seem to provide efficacy for EIEE13 patients, it does so at a cost. Efficacy is only achieved at very high doses where the significant adverse effects are tolerated only because the patients are in such dire need. Adverse effects commonly associated with phenytoin therapy include hepatic necrosis, hypertrichosis, nervousness, tremor of hands, numbness, dizziness, drowsiness, tremor, depression, confusion, fatigue, constipation, vertigo, ataxia, mental status changes, myasthenia, mood changes, restlessness, irritability, and excitement. It seems likely that a drug that selectively targets Na 1.6 would retain efficacy while reducing its adverse event burden.
• SCN8A med and SCN8A med/j0 mice are resistant to seizures induced by chemical insult (flurothyl, kainic acid, and picrotoxin) (Martin, M.S. et al., Human Molecular Genetics (2007), Vol. 16, pp. 2892-2899; Hawkins, N.A. et al., Neurobiology of Disease (201 1), Vol. 41 , pp. 655-660; and Makinson, C.D. et al., Neurobiology of Disease (2014), Vol. 68, pp. 16-25).
• chemical insult flurothyl, kainic acid, and picrotoxin
• mice when SCN8A med/j0 mice are crossed with SCN1A nu " mutant mice to produce a mouse that is heterozygous for both the SCN1A nu " allele and the SCN8A med/j0 allele the double mutant mice have a much improved seizure and cognitive phenotype than those with only an SCN1A nu " mutation (Martin, M.S. et al., Human Molecular Genetics (2007), Vol. 16, pp. 2892- 2899). Such mice have a spontaneous seizure and death rate similar to wild type mice and their seizure threshold after chemical insult is also increased.
• Voltage-gated sodium channel antagonism is the most common mechanism of widely prescribed antiepileptic drugs (AED’s) (Ochoa, J.R. et al., Sodium Channel Blockers. In: Antiepileptic Drugs (2016), Vol. (Benbadis, S., ed) Medscape News & Perspectives).
• AED antiepileptic drugs
• Carbamazepine, Eslicarbazepine, Oxcarbazepine, Lacosamide, Lamotrigine, Phenytoin, Rufinamide and Zonisamide are all believed to act primarily by blocking that function of Na ⁇ channels. Despite the presumed mechanism of action, these drugs are relatively promiscuous.
• the present invention is directed to benzenesulfonamide compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions of the invention for the treatment of diseases or conditions associated with the activity of voltage-gated sodium channels, particularly, Na 1.6 activity, such as epilepsy and/or epileptic seizure disorder.
• this invention is directed to compounds of formula (I):
• q 1 or 2;
• r is 1 or 2;
• R 1 is hydrogen or alkyl
• R 2 is thiazolyl, isothiazolyl or isoxazolyl
• R 3a and R 3b are each independently hydrogen or alkyl
• each R 4 is independently halo or alkyl
• R 5 is halo
• each R 6 is independently halo or alkoxy
• R 7 is azabicyclo[2.2.1]heptanylalkyl or R 7 is ((methyl)(prop-2-yl)amino)alkyl when r is 2 and at least one R 6 is alkoxy;
• the compounds of the invention which are compounds of formula (I) as described above, as individual stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or as pharmaceutically acceptable salts, solvates or prodrugs thereof, are useful in treating diseases or conditions associated with voltage-gated sodium channels, preferably Na 1.6.
• the compounds of the invention are Na 1.6 inhibitors. More preferably, the compounds of the invention show selectivity of inhibiting Na 1.6 as compared with inhibiting Na 1.5 and/or Na 1.1. Without wishing to be bound by theory, such selectivity is thought to advantageously reduce any side effects which may be associated with the inhibition of Na 1.5 and/or Na 1.1.
• the invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• the invention provides methods for the treatment of epilepsy and/or epileptic seizure disorder in a mammal, preferably a human, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention, as set forth above, as a
• pharmaceutically acceptable salt, solvate or prodrug thereof or a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.
• the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder in a mammal where activation or hyperactivity of Na 1.6 is implicated in the disease, condition or disorder, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a
• pharmaceutically acceptable salt, solvate or prodrug thereof or a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.
• the invention provides methods of treating or ameliorating, but not preventing, epilepsy and/or epileptic seizure disorder in a mammal, wherein the methods comprise administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention, as set forth above, as a
• pharmaceutically acceptable salt, solvate or prodrug thereof or a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient.
• the invention provides pharmaceutical therapy in another aspect.
• the present invention relates to a
• composition combining compounds of the present invention with established or future therapies for the indications listed herein.
• this invention is directed to methods of selectively inhibiting a first voltage-gated sodium channel in a mammal over a second voltage-gated sodium channel, wherein the method comprises administering to the mammal a inhibitory amount of a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, or a pharmaceutical composition comprising a inhibitory amount of a compound of the invention, as set forth above, as a
• this invention is directed to the use of the compounds of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or the use of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as set forth above, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment of a disease or condition associated with the activity of a voltage-gated sodium channel, preferably Na 1.6, in a mammal and preferably wherein the disease or condition is epilepsy and/or epileptic seizure disorder.
• C 7 -Ci 2 alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms
• C 4 -Ci 2 cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms.
• the total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described.
• Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms, more preferably one to six carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (/so-propyl), n-butyl, n-pentyl, 1 , 1 -dimethylethyl (f-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
• an alkyl group may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 20 , -0C(0)-R 2 °, -N(R 20 ) 2 , -C(0)R 20 , -C(0)0R 2 °, -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 22 , -N(R 20 )C(O)R 22 , -N(R 20 )S(O) P R 22 (where p is 1 to 2), -S(0) p 0R 22 (where p is 1 to 2), -S(0) t R 22 (where t is 0 to 2), and -S(O) p N(R 20 ) 2
• each R 22 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl.
• alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably two to eight carbon atoms and which is attached to the rest of the molecule by a single bond, e.g., ethenyl, prop-1- enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like.
• an alkenyl group may be optionally substituted by one of the following groups: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo,
• heterocyclylalkyl heteroaryl or heteroarylalkyl.
• Alkoxy refers to a radical of the formula -OR a where R a is an alkyl group as defined above, e.g., methoxy, ethoxy, n-propoxy, isopropoxy and the like. When specifically stated in the specification, the alkyl group may be optionally substituted as defined above for an alkyl radical. Preferably, “alkoxy” refers to methoxy or isopropoxy.
• Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group or linking two parts of the molecule, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, n-butylene, and the like.
• the alkylene chain may optionally contain one or more heteroatoms wherein a carbon in the alkylene chain is replaced with a heteroatom selected from oxygen, nitrogen or sulfur.
• alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond or is attached to two parts of the molecule through a single bond at each point of attachment.
• an alkylene chain may be optionally substituted by one of the following groups: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, trimethylsilanyl, -OR 20 , -OC(0)-R 20 , -N(R 20 ) 2 , -C(0)R 20 , -C(0)OR 20 , -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 22 ,
• each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; and each R 22 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl.
• Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
• the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may included fused or bridged ring systems.
• Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s- indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
• an aryl group may be optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, aryl, aralkyl, cycloalkyl, cycloalkyl alkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 21 -OR 20 , -R 21 -OC(0)-R 20 , -R 21 -N(R 20 ) 2 , -R 21 -N(R 20 )-R 23 -OR 20 , -R 21 -C(0)R 20 ,
• the optional substituents on an optionally substituted aryl group for R 1 herein are alkyl, optionally substituted cycloalkyl, halo, haloalkyl, cyano, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl -R 21 -OR 20 and -R 21 -N(R 20 ) 2 , (where R 20 and R 21 are as defined above).
• Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic
• hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
• Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and the like. When specifically stated in the specification, a cycloalkyl group may be optionally substituted by one or more substituents
• alkyl independently selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, oxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 21 -OR 20 , -R 21 -0C(0)-R 2 °,
• each R 23 is a direct bond or a straight or branched alkylene chain.
• Cycloalkylalkyl refers to a radical of the formula -R b R g where R b is an alkylene chain as defined above and R g is a cycloalkyl radical as defined above.
• R b is an alkylene chain as defined above
• R g is a cycloalkyl radical as defined above.
• the alkylene chain and/or the cycloalkyl radical may be optionally substituted as defined above for optionally substituted alkylene chain and optionally substituted cycloalkyl.
• Halo refers to bromo, chloro, fluoro or iodo.
• Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2- fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.
• the alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl group.
• Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
• the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused, bridged and spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
• heterocyclyl radicals include, but are not limited to, azetidinyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1-azaspiro[3.3]heptan-1-yl, 5-azaspiro[2.3]hexan-5-yl, azabicyclo[2.2.1]heptanyl, 2- oxa-6-azaspiro[3.3]heptan-6-yl, 1-oxa-6-azaspiro[3.4]octan-6-yl, 1-oxa-6- azaspiro[3.3]heptan-6-yl, 6-oxa-1-azaspiro[3.3]heptan-1-yl, 6-azaspiro[3.4]octan-6-yl, 7-oxa-2-azaspiro[3.5]nonan-2-yl, 2,6-diazaspiro[3.3]heptan-2-yl, dioxolanyl, dioxinyl, thienyl[
• a heterocyclyl group may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 21 -OR 20 , -R 21 -OC(0)-R 20 , -R 21 -N(R 20 )-R 23 -OR 20 , -R 21 -N(R 20 ) 2 , -R 21 -C(0)R 20 , -R 21 -C(0)OR 20 , -R 21 -C(0)N(R 20 ) 2 , -R 21 -N(R 20 )C(O)OR 22 , -R 21
• each R 20 is independently hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl; each R 21 is independently a direct bond or a straight or branched alkylene chain; each R 22 is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl,
• heterocyclylalkyl heteroaryl or heteroarylalkyl, and each R 23 is a direct bond or a straight or branched alkylene chain.
• Heterocyclylalkyl refers to a radical of the formula -R b R h where R b is an alkylene chain as defined above and R h is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom.
• the alkylene chain of the heterocyclylalkyl radical may be optionally substituted as defined above for an optionally substituted alkylene chain.
• the heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for an optionally substituted heterocyclyl group.
• the optional substituents on the optionally substituted heterocyclylalkyl group for R 5 herein are halo.
• Azabicyclo[2.2.1]heptanylalkyl refers to a radical of the formula -R b R j where R is an alkylene chain as defined above and R j is azabicyclo[2.2.1]heptanyl.
• R is a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, containing no unsaturation and having from one to eight carbon atoms, preferably a straight divalent hydrocarbon chain consisting of one carbon or a branched divalent carbon consisting of two carbons.
• ((Methyl)(prop-2-yl)amino)alkyl refers to the radical of the formula -R b N(R a ) 2 where R is an alkylene chain as defined above and one R a is methyl and the other R a is prop-2-yl.
• R is a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, containing no unsaturation and having from one to eight carbon atoms, preferably one carbon atom.
• Heteroaryl refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
• the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
• Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl,
• a heteroaryl group may be optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, oxo, thioxo, nitro, thioxo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, -R 21 -OR 20 , -R 21 -0C(0)-R 2 °, -R 21 -N(R 20 )-R 23 -OR 20 , -R 21 -N(R 20 ) 2 , -R 21 -C(0)R 20 , -R 21 -C(0)OR 20 , -R 21 -C(O)N(R 20 ) 2 , -R 21 -N(R
• each R 23 is a direct bond or a straight or branched alkylene chain.
• the optional substituents on an optionally substituted bicyclic heteroaryl group for R 1 herein are halo.
• the optional substituents on an optionally substituted monocyclic heteroaryl group for R 1 herein are alkyl.
• Heteroarylalkyl refers to a radical of the formula -R b Ri where R b is an alkylene chain as defined above and R, is a heteroaryl radical as defined above.
• R b is an alkylene chain as defined above and R, is a heteroaryl radical as defined above.
• the heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for an optionally substituted heteroaryl group.
• the alkylene chain part of the heteroarylalkyl radical may be optionally substituted as defined above for an optionally substituted alkylene chain.
• Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention.
• prodrug refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable.
• a prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention.
• Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood.
• the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)).
• prodrugs are provided in Higuchi, T., et ai, "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American
• prodrug is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject.
• Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
• Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
• Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like.
• the invention disclosed herein is also meant to encompass all pharmaceutically acceptable compounds of formula (I) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
• isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 CI, 123 l, and 125 l, respectively.
• isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 CI, 123 l, and 125 l, respectively.
• These radiolabelled compounds could be useful to help determine or measure the effectiveness of the compounds, by characterizing, for example, the site or mode of action on the sodium channels, or binding affinity to pharmacologically important site of action on the sodium channels.
• isotopically-labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
• the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
• the compounds of formula (I) are enriched with deuterium.
• deuterated compounds can be achieved by methods known to one skilled in the art, such as exchanging protons with deuterium or by synthesizing the molecule with enriched starting materials.
• Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples and Preparations as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
• the invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically are identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.
• an animal such as rat, mouse, guinea pig, monkey, or to human
• Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
• “Mammal” includes humans and both domestic animals such as laboratory animals and household pets, (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.
• Optional or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
• optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution ("unsubstituted).
• substitutents on the functional group are also “optionally substituted” and so on, for the purposes of this invention, such iterations are limited to five, preferably such iterations are limited to two.
• “Pharmaceutically acceptable carrier, diluent or excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
• “Pharmaceutically acceptable salt” includes both acid and base addition salts.
• “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1 , 2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulf
• “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, /V-ethylpiperidine, polyamine resins and the like.
• Particularly preferred organic bases are is
• solvate refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
• the solvent may be water, in which case the solvate may be a hydrate.
• the solvent may be an organic solvent.
• the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
• the compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
• a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all
• “Therapeutically effective amount” refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a sodium channel-mediated disease or condition in the mammal, preferably a human.
• the amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
• Treating covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
• the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
• the compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as ( R )- or (S)- or, as (D)- or (L)- for amino acids.
• the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
• Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallisation.
• stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
• the present invention contemplates various stereoisomers and mixtures thereof and includes enantiomers, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another. See, for example, Smith, M.B. and J. March, March's Advanced Organic Chemistry: Reactions,
• a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
• the present invention includes tautomers of any said compounds.
• Enantiomers refer to asymmetric molecules that can exist in two different isomeric forms which have different configurations in space. Other terms used to designate or refer to enantiomers include “stereoisomers” (because of the different arrangement or stereochemistry around the chiral center; although all enantiomers are stereoisomers, not all stereoisomers are enantiomers) or “optical isomers” (because of the optical activity of pure enantiomers, which is the ability of different pure
• ft and S for the absolute configuration of an enantiomer of the invention may appear as a prefix or as a suffix in the name of the compound; they may or may not be separated from the enantiomer name by a hyphen; they may or may not be hyphenated; and they may or may not be surrounded by parentheses.
• a bond to a substituent and/or a bond that links a molecular fragment to the remainder of a compound may be shown as intersecting one or more bonds in a ring structure. This indicates that the bond may be attached to any one of the atoms that constitutes the ring structure, so long as a hydrogen atom could otherwise be present at that atom. Where no particular substituent(s) is identified for a particular position in a structure, then hydrogen(s) is present at that position.
• the bond attaching the R 30 substituent can be on any of the carbons, including the carbon to which the R 31 is attached, provided that the valency allows for such an attachment:
• Resolution or “resolving” when used in reference to a racemic compound or a racemic mixture of a compound of the invention refers to the separation of the racemic compound or a racemic mixture into its two enantiomeric forms (/.e., (+) and (-); (ft) and (S) forms).
• One aspect of the invention are compounds of formula (I), as set forth above in the Summary of the Invention, as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• One embodiment of the invention are compounds of formula (I) wherein R 7 is azabicyclo[2.2.1]heptanylalkyl.
• preferred embodiments are selected from:
• R 7 is azabicyclo[2.2.1]heptanylalkyl
• another embodiment are compounds of formula (I) wherein R 2 is thiazolyl.
• one further embodiment are compounds of formula (I) wherein r is 1.
• preferred embodiments are selected from:
• R 2 is thiazolyl
• another further embodiment are compounds of formula (I) where r is 2.
• preferred embodiments are selected from:
• R 7 is azabicyclo[2.2.1]heptanylalkyl
• another embodiment are compounds of formula (I) wherein R 2 is isoxazolyl.
• preferred embodiments are compounds of formula (I) selected from:
• Another embodiment of the invention are compounds of formula (I) wherein R 7 is azabicyclo[2.2.1]heptanylalkyl.
• a further embodiment are compounds of formula (I) where R 7 is ((methyl)(prop-2-yl)amino)alkyl, provided that r is 2 and at least one R 6 is alkoxy.
• a further embodiment are compounds of formula (I) wherein R 2 is isothiazolyl.
• R 7 is ((methyl)(prop-2-yl)amino)alkyl, r is 2 and at least one R 6 is alkoxy
• another further embodiment are compounds of formula (I) wherein R 2 is thiazolyl.
• preferred compounds of formula (I) are selected from:
• R 7 is ((methyl)(prop-2-yl)amino)alkyl, r is 2 and at least one R 6 is alkoxy
• another further embodiment are compounds of formula (I) wherein R 2 is isoxazoyl.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is in the ortho position relative to the -S(0) 2 -N(H)-R 2 substituent.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is in the ortho position relative to -C(R 3a )(R 3b )-.
• Another embodiment of the invention are compounds of formula (I) wherein one R 6 is in the ortho position relative to -C(R 3a )(R 3b )-.
• Another embodiment of the invention are compounds of formula (I) wherein R 5 is fluoro.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is fluoro.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is chloro.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is methyl.
• Another embodiment of the invention are compounds of formula (I) wherein one R 4 is fluoro and another R 4 is methyl.
• Another embodiment of the invention are compounds of formula (I) wherein one R 6 is fluoro.
• Another embodiment of the invention are compounds of formula (I) wherein one R 6 is fluoro and another R 6 is methoxy.
• Another embodiment of the invention are compounds of formula (I) wherein one R 6 is fluoro and another R 6 is isopropoxy.
• Another embodiment of the invention are compounds of formula (I) wherein one R 6 is fluoro and another R 6 is fluoro.
• Another embodiment of the invention is a method of using the compounds of formula (I) as standards or controls in in vitro or in vivo assays in determining the efficacy of test compounds in modulating voltage-dependent sodium channels.
• Another embodiment of the invention are compounds of formula (la), compounds of formula (lb), compounds of formula (lc), compounds of formula (Id), compounds of formula (Id), compounds of formula (le), compounds of formula (If), compounds of formula (Ig), compounds of formula (Ih), compounds of formula (li), compounds of formula (Ij) or compounds of formula (Ik), as individual stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, as described below in the Preparation of the Compounds of the Invention.
• Another embodiment of the invention is a method of preparing a compound of formula (la), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 1.
• Another embodiment of the invention is a method of preparing a compound of formula (lb), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 2.
• Another embodiment of the invention is a method of preparing a compound of formula (lc), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 3.
• Another embodiment of the invention is a method of preparing a compound of formula (If), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 3.
• Another embodiment of the invention is a method of preparing a compound of formula (Ig), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 3.
• Another embodiment of the invention is a method of preparing a compound of formula (Id), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 4.
• Another embodiment of the invention is a method of preparing a compound of formula (le), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 5.
• Another embodiment of the invention is a method of preparing a compound of formula (la), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 6.
• Another embodiment of the invention is a method of preparing a compound of formula (Ih), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 7.
• Another embodiment of the invention is a method of preparing a compound of formula (li), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 8.
• Another embodiment of the invention is a method of preparing a compound of formula (Ij), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 9.
• Another embodiment of the invention is a method of preparing a compound of formula (Ik), as an individual stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt thereof, as described herein in Reaction Scheme 9.
• any embodiment of the compounds of the invention, as set forth above, and any specific substituent set forth herein for a particular R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 and R 7 substituent in the compounds of the invention, as set forth above, may be independently combined with other embodiments and/or substituents of compounds of the invention to form embodiments of the inventions not specifically set forth above.
• Another aspect of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the invention, as described above, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• Another aspect of the invention is a method of treating a disease or a condition associated with Na 1.6 activity in a mammal wherein the disease or condition is epilepsy and/or epileptic seizure disorder and wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention, as described above, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• the epilepsy or epileptic seizure disorder is selected from photosensitive epilepsy, self-induced syncope, intractable epilepsy, Angelman syndrome, benign rolandic epilepsy, CDKL5 disorder, childhood and juvenile absence epilepsy, Dravet syndrome, frontal lobe epilepsy, Glutl deficiency syndrome, hypothalamic hamartoma, infantile spasms/West's syndrome, juvenile myoclonic epilepsy, Landau-Kleffner syndrome, Lennox-Gastaut syndrome (LGS), epilepsy with myoclonic-absences, Ohtahara syndrome, Panayiotopoulos syndrome, PCDH19 epilepsy, progressive myoclonic epilepsies, Rasmussen's syndrome, ring chromosome 20 syndrome, reflex epilepsies, temporal lobe epilepsy, Lafora
• the epilepsy or epileptic seizure disorder is selected from Dravet syndrome, infantile spasms/West's syndrome, temporal lobe epilepsy, Lennox-Gastaut syndrome (LGS), generalized epilepsy with febrile seizures + and early infantile epileptic encephalopathy.
• Another aspect of the invention is a method of decreasing ion flux through Na ⁇ l .6 in a mammalian cell, wherein the method comprises contacting the cell with a compound of the invention, as described above, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• Another aspect of the invention is a method of selectively inhibiting a first voltage-gated sodium channel over a second voltage-gated sodium channel in a mammal, wherein the method comprises administering to the mammal a modulating amount of a compound of the invention, as described above, as a stereoisomer, enantiomer or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
• the first voltage-gated sodium channel is
• the first voltage-gated sodium channel is Na 1.6 and the second voltage-gated sodium channel is Na 1.5.
• the first voltage-gated sodium channel is Na ⁇ l .6 and the second voltage-gated sodium channel is Na ⁇ l .1.
• the compounds of the invention modulate, preferably inhibit, ion flux through a voltage-dependent sodium channel, preferably Na 1.6, in a mammal, especially in a human. Any such modulation, whether it be partial or complete inhibition or prevention of ion flux, is sometimes referred to herein as "blocking" and corresponding
• the compounds of the invention modulate the activity of a voltage-gated sodium channel downwards by inhibiting the voltage-dependent activity of the sodium channel, and/or reduce or prevent sodium ion flux across a cell membrane by preventing sodium channel activity such as ion flux.
• the compounds of the invention inhibit the ion flux through a voltage- dependent sodium channel, preferably Na 1.6.
• the compounds of the invention are state or frequency dependent modifiers of the sodium channel, having a low affinity for the rested/closed state and a high affinity for the inactivated state. These compounds are likely to interact with overlapping sites located in the inner cavity of the sodium conducting pore of the channel similar to that described for other state-dependent sodium channel blockers (Cestele, S., et ai, op. cit.). These compounds may also be likely to interact with sites outside of the inner cavity and have allosteric effects on sodium ion conduction through the channel pore.
• the compounds of the invention are voltage-gated sodium channel inhibitors, preferably Na 1.6 inhibitors, and are therefore useful for treating diseases and conditions, preferably epilepsy and/or epileptic seizure disorder, in mammals, preferably humans, and other organisms, including all those human diseases and conditions which are the result of aberrant voltage-dependent sodium channel biological activity, preferably aberrant Na 1.6 activity, or which may be ameliorated by modulation of voltage-dependent sodium channel biological activity.
• diseases and conditions preferably epilepsy and/or epileptic seizure disorder
• diseases and conditions preferably epilepsy and/or epileptic seizure disorder
• mammals preferably humans, and other organisms, including all those human diseases and conditions which are the result of aberrant voltage-dependent sodium channel biological activity, preferably aberrant Na 1.6 activity, or which may be ameliorated by modulation of voltage-dependent sodium channel biological activity.
• the compounds of the invention i.e., the compounds of formula (I), as set forth above in the Summary of the Invention, as individual stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or as pharmaceutically acceptable salts, solvates or prodrugs thereof, are useful for treating diseases and conditions in mammals, preferably humans, which are the result of aberrant voltage-dependent Na ⁇ l .6 biological activity or which may be ameliorated by the modulation, preferably the inhibition, of Na ⁇ l .6 biological activity.
• the compounds of the invention selectively inhibit Na 1.6 over Na 1.5 and/or Na 1.1.
• a disease, disorder or condition associated with Na 1.6 activity includes, but is not limited to, epilepsy and/or epileptic seizure disorder.
• epilepsy and/or epileptic seizure disorders include, but are not limited to,
• photosensitive epilepsy self-induced syncope, intractable epilepsy, Angelman syndrome, benign rolandic epilepsy, CDKL5 disorder, childhood and juvenile absence epilepsy, Dravet syndrome, frontal lobe epilepsy, Glutl deficiency syndrome, hypothalamic hamartoma, infantile spasms/West's syndrome, juvenile myoclonic epilepsy, Landau-Kleffner syndrome, Lennox-Gastaut syndrome (LGS), epilepsy with myoclonic-absences, Ohtahara syndrome, Panayiotopoulos syndrome, PCDH19 epilepsy, progressive myoclonic epilepsies, Rasmussen's syndrome, ring chromosome 20 syndrome, reflex epilepsies, temporal lobe epilepsy, Lafora progressive myoclonus epilepsy, neurocutaneous syndromes, tuberous sclerosis complex, early infantile epileptic encephalopathy, early onset epileptic encephalopathy, generalized
• the present invention therefore relates to compounds, pharmaceutical compositions and methods of using the compounds and pharmaceutical compositions for the treatment of diseases or conditions associated by the activity of Na 1.6 in a mammal, preferably a human, by administering to the mammal, preferably the human, in need of such treatment an effective amount of a compound of the invention or an pharmaceutical composition comprising a compound of the invention.
• the general value of the compounds of the invention in inhibiting the Na 1.6 ion flux can be determined using the assays described below in the Biological Assays section.
• the general value of the compounds in treating conditions and diseases in humans may be established in industry standard animal models for demonstrating the efficacy of compounds in treating epilepsy and/or epileptic seizure disorder. Animal models of human epileptic conditions have been developed that result in reproducible sensory deficits over a sustained period of time that can be evaluated by sensory testing.
• Both assays involve an electrical insult applied with electrodes placed on the corneas or ears in order to provoke an acute seizure. Acute seizures may also be induced chemically, for instance by administration of the proconvulsant ether compound flurothyl (Makinson, C.D. et ai., Exp. Neurol. (2016), Vol. 275, Pt 1 , pp. 46-58).
• Genetic epilepsies have been linked to many distinct genes, including multiple voltage gated sodium channel genes. Genetically modified mice can be created that harbor mutations identified in human patients. In some cases these genetic defects
• EIEE6 early infantile epileptic encephalopathy 6
• SCN1A gene that encodes the Na 1.1 voltage gated sodium channel
• Models of EIEE13 have likewise been created by mutating the SCN6A gene that encodes the Na 1.6 voltage gated sodium channel (Wagnon, J.L. et ai, Human Molecular Structure
• the present invention readily affords many different means for identification of Na 1.6 inhibitory agents that are useful as therapeutic agents. Identification of Na 1.6 inhibitors can be assessed using a variety of in vitro and in vivo assays, e.g., measuring current, measuring membrane potential, measuring ion flux, (e.g., sodium or guanidinium), measuring sodium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.
• in vitro and in vivo assays e.g., measuring current, measuring membrane potential, measuring ion flux, (e.g., sodium or guanidinium), measuring sodium concentration, measuring second messengers and transcription levels, and using e.g., voltage-sensitive dyes, radioactive tracers, and patch-clamp electrophysiology.
• One such protocol involves the screening of chemical agents for ability to modulate the activity of a sodium channel thereby identifying it as a modulating agent.
• Throughput of test compounds is an important consideration in the choice of screening assay to be used. In some strategies, where hundreds of thousands of compounds are to be tested, it is not desirable to use low throughput means. In other cases, however, low throughput is satisfactory to identify important differences between a limited number of compounds. Often it will be necessary to combine assay types to identify specific sodium channel modulating compounds.
• Electrophysiological assays using patch clamp techniques is accepted as a gold standard for detailed characterization of sodium channel compound interactions, and as described in Bean et al., op. cit. and Leuwer, M., et al., op. cit.
• LTS manual low-throughput screening
• MTS medium-throughput screening
• HTS high-throughput screening
• Planar electrodes are capable of achieving high- resistance, cells-attached seals followed by stable, low-noise whole-cell recordings that are comparable to conventional recordings.
• a suitable instrument is the PatchXpress 7000A (Axon Instruments Inc, Union City, CA).
• PatchXpress 7000A Axon Instruments Inc, Union City, CA.
• a variety of cell lines and culture techniques, which include adherent cells as well as cells growing spontaneously in suspension are ranked for seal success rate and stability. Immortalized cells (e.g.
• HEK and CHO stably expressing high levels of the relevant sodium ion channel can be adapted into high-density suspension cultures.
• Binding assays are also available. Designs include traditional radioactive filter based binding assays or the confocal based fluorescent system available from Evotec OAI group of companies (Hamburg, Germany), both of which are HTS.
• Radioactive flux assays can also be used.
• channels are stimulated to open with veratridine or aconitine and held in a stabilized open state with a toxin, and channel blockers are identified by their ability to prevent ion influx.
• the assay can use radioactive 22 [Na] and 14 [C] guanidinium ions as tracers. FlashPlate & Cytostar-T plates in living cells avoids separation steps and are suitable for HTS.
• Scintillation plate technology has also advanced this method to HTS suitability.
• HTS FLIPR system membrane potential kit
• Sodium dyes can be used to measure the rate or amount of sodium ion influx through a channel. This type of assay provides a very high information content regarding potential channel blockers. The assay is functional and would measure Nan- influx directly. CoroNa Red, SBFI and/or sodium green (Molecular Probes, Inc.
• FRET based voltage sensors are used to measure the ability of a test compound to directly block Na influx.
• HTS systems include the VIPRTM II FRET system (Aurora Biosciences Corporation, San Diego, CA, a division of Vertex Pharmaceuticals, Inc.) which may be used in conjunction with FRET dyes, also available from Aurora Biosciences.
• This assay measures sub-second responses to voltage changes. There is no requirement for a modifier of channel function.
• the assay measures depolarization and hyperpolarizations, and provides ratiometric outputs for quantification.
• a somewhat less expensive MTS version of this assay employs the FLEXstationTM (Molecular Devices Corporation) in conjunction with FRET dyes from Aurora Biosciences. Other methods of testing the compounds disclosed herein are also readily known and available to those skilled in the art.
• SAR structure-activity relationship
• Modulating agents so identified are then tested in a variety of in vivo models so as to determine if they are useful in treating the disease or condition associated with the activity of the sodium channel of interest, preferably Na 1.6, with minimal adverse events.
• the assays described below in the Biological Assays Section are useful in assessing the biological activity of the instant compounds.
• the efficacy of a compound of the invention is expressed by its IC 50 value ("Inhibitory Concentration - 50%”), which is the measure of the amount of compound required to achieve 50% inhibition of the activity of the target sodium channel over a specific time period.
• the compounds of the invention can be used in in vitro or in vivo studies as exemplary agents for comparative purposes to find other compounds also useful in treatment of, or protection from, the various diseases disclosed herein.
• Another aspect of the invention relates to inhibiting Na 1.6 activity in a biological sample or a mammal, preferably a human, which method comprises administering to the mammal, preferably a human, or contacting said biological sample with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).
• biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
• Inhibition of Na ⁇ l .6 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
• compositions described herein which comprise a pharmaceutically acceptable excipient and one or more compounds of the invention, as set forth above in the Summary of the Invention, as a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, can be used in the preparation of a medicament for the treatment of diseases or conditions associated with voltage-gated sodium channel activity, preferably Na 1.6 activity, in a mammal.
• the present invention also relates to pharmaceutical composition containing the compounds of the invention disclosed herein.
• the present invention relates to a composition comprising compounds of the invention in a pharmaceutically acceptable carrier, excipient or diluent and in an amount effective to modulate, preferably inhibit, ion flux through a voltage-dependent sodium channel to treat sodium channel mediated diseases, such as epilepsy and/or epileptic seizure disorder, when administered to an animal, preferably a mammal, most preferably a human patient.
• sodium channel mediated diseases such as epilepsy and/or epileptic seizure disorder
• compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
• compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
• Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units.
• composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in
• compositions useful herein also contain a pharmaceutically acceptable carrier, including any suitable diluent or excipient, which includes any pharmaceutical agent that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity.
• pharmaceutically acceptable carriers include, but are not limited to, liquids, such as water, saline, glycerol and ethanol, and the like. A thorough discussion of pharmaceutically acceptable carriers, diluents, and other excipients is presented in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J., current edition).
• a pharmaceutical composition of the invention may be in the form of a solid or liquid.
• the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form.
• the carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
• the pharmaceutical composition When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
• the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
• a solid composition will typically contain one or more inert diluents or edible carriers.
• binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
• excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like
• lubricants such as magnesium stearate or Sterotex
• glidants such as colloidal silicon dioxide
• sweetening agents such as sucrose or saccharin
• a flavoring agent such as peppermint, methyl sal
• the pharmaceutical composition when in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
• a liquid carrier such as polyethylene glycol or oil.
• the pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension.
• the liquid may be for oral
• preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
• composition intended to be administered by injection one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
• the liquid pharmaceutical compositions of the invention may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
• the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
• Physiological saline is a preferred adjuvant.
• An injectable pharmaceutical composition is preferably sterile.
• a liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 0.01 % of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition.
• Preferred oral pharmaceutical compositions contain between about 4% and about 50% of the compound of the invention.
• Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention.
• the pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base.
• the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
• Thickening agents may be present in a pharmaceutical composition for topical administration.
• the composition may include a transdermal patch or iontophoresis device.
• Topical formulations may contain a concentration of the compound of the invention from about 0.1 to about 10% w/v (weight per unit volume).
• the pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug.
• the composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient.
• bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
• the pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit.
• the composition may include materials that form a coating shell around the active ingredients.
• the materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents.
• the active ingredients may be encased in a gelatin capsule.
• the pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound.
• Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.
• the pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol.
• aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One skilled in the art, without undue experimentation may determine preferred aerosols.
• compositions of the invention may be prepared by methodology well known in the pharmaceutical art.
• a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution.
• a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
• Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
• the compounds of the invention, or their pharmaceutically acceptable salts are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
• a therapeutically effective daily dose is (for a 70 Kg mammal) from about 0.001 mg/Kg (/.e., 0.07 mg) to about 100 mg/Kg (/.e.,
• a therapeutically effective dose is (for a 70 Kg mammal) from about 0.01 mg/Kg (/.e., 0.7 mg) to about 50 mg/Kg (/.e., 3.5 g); more preferably a therapeutically effective dose is (for a 70 Kg mammal) from about 1 mg/kg (/.e., 70 mg) to about 25 mg/Kg (/.e., 1.75 g).
• the total dose required for each treatment can be administered by multiple doses or in a single dose over the course of the day, if desired. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
• the diagnostic pharmaceutical compound or composition can be administered alone or in conjunction with other diagnostics and/or pharmaceuticals directed to the pathology, or directed to other symptoms of the pathology.
• the recipients of administration of compounds and/or compositions of the invention can be any vertebrate animal, such as mammals.
• the preferred recipients are mammals of the Orders Primate (including humans, apes and monkeys), Arteriodactyla (including horses, goats, cows, sheep, pigs), Rodenta (including mice, rats and hamsters), Lagamorpha (including rabbits) and Carnivora (including cats, and dogs).
• the preferred recipients are turkeys, chickens and other members of the same order. The most preferred recipients are humans.
• a pharmaceutical composition according to the invention for topical applications, it is preferred to administer an effective amount of a pharmaceutical composition according to the invention to target area, e.g., skin surfaces, mucous membranes, and the like, which are adjacent to peripheral neurons which are to be treated.
• This amount will generally range from about 0.0001 mg to about 1 g of a compound of the invention per application, depending upon the area to be treated, whether the use is diagnostic, prophylactic or therapeutic, the severity of the symptoms, and the nature of the topical vehicle employed.
• a preferred topical preparation is an ointment, wherein about 0.001 to about 50 mg of active ingredient is used per cc of ointment base.
• the pharmaceutical composition can be formulated as transdermal compositions or transdermal delivery devices ("patches"). Such compositions include, for example, a backing, active compound reservoir, a control membrane, liner and contact adhesive. Such transdermal patches may be used to provide continuous pulsatile, or on demand delivery of the compounds of the present invention as desired.
• compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
• Controlled release drug delivery systems are well-known in the art and include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations.
• compositions of the invention can also be delivered through intra-nasal drug delivery systems for local, systemic, and nose-to-brain medical therapies.
• Controlled Particle Dispersion (CPD)TM technology traditional nasal spray bottles, inhalers or nebulizers are known by those skilled in the art to provide effective local and systemic delivery of drugs by targeting the olfactory region and paranasal sinuses.
• the invention also relates to an intravaginal shell or core drug delivery device suitable for administration to the human or animal female.
• the device may be comprised of the active pharmaceutical ingredient in a polymer matrix, surrounded by a sheath, and capable of releasing the compound in a substantially zero order pattern on a daily basis similar to devices used to apply testosterone as described in PCT
• the compounds of the invention may be usefully combined with one or more other compounds of the invention or one or more other therapeutic agent or as any combination thereof, in the treatment of diseases and conditions associated with voltage-gated sodium channel activity.
• a compound of the invention may be administered simultaneously, sequentially or separately in combination with other therapeutic agents, including, but not limited to:
• opiates analgesics e.g., morphine, heroin, cocaine, oxymorphine, levorphanol, levallorphan, oxycodone, codeine, dihydrocodeine, propoxyphene, nalmefene, fentanyl, hydrocodone, hydromorphone, meripidine, methadone, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine and
• non-opiate analgesics e.g., acetaminophen, salicylates (e.g., aspirin);
• nonsteroidal anti-inflammatory drugs e.g., ibuprofen, naproxen, fenoprofen, ketoprofen, celecoxib, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin and zomepirac;
• NSAIDs nonsteroidal anti-inflammatory drugs
• anticonvulsants e.g., carbamazepine, oxcarbazepine, lamotrigine, valproate, topiramate, gabapentin and pregabalin;
• antidepressants such as tricyclic antidepressants, e.g., amitriptyline,
• COX-2 selective inhibitors e.g., celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, and lumiracoxib;
• alpha-adrenergics e.g., doxazosin, tamsulosin, clonidine, guanfacine,
• barbiturate sedatives e.g., amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal and thiopental;
• tachykinin (NK) antagonist particularly an NK-3, NK-2 or NK-1 antagonist, e.g., (aR, 9R)-7-[3,5-bis(trifluoromethyl)benzyl)]-8,9,10,11-tetrahydro-9-methyl-5-(4- methylphenyl)-7H-[1 ,4]diazocino[2,1-g][1 ,7]-naphthyridine-6-13-dione (TAK- 637), 5-[[2R,3S)-2-[(1 R)-1-[3,5-bis(trifluoromethylphenyl]ethoxy-3-(4- fluorophenyl)-4-morpholinyl]-methyl]-1 ,2-dihydro-3H-1 ,2,4-triazol-3-one (MK- 869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy5- (trifluoromethoxy)phenyl
• coal-tar analgesics in particular paracetamol
• serotonin reuptake inhibitors e.g., paroxetine, sertraline, norfluoxetine
• noradrenaline noradrenaline (norepinephrine) reuptake inhibitors, e.g., maprotiline
• lofepramine mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine (Vivalan®)), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S.S)-reboxetine, and venlafaxine duloxetine neuroleptics sedative/anxiolytics;
• reboxetine in particular (S.S)-reboxetine
• venlafaxine duloxetine sedative/anxiolytics
• venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine, milnacipran and imipramine; acetylcholinesterase inhibitors such as donepezil;
• 5-HT 3 antagonists such as ondansetron
• metabotropic glutamate receptor (mGluR) antagonists metabotropic glutamate receptor (mGluR) antagonists
• local anaesthetic such as mexiletine and lidocaine
• corticosteroid such as dexamethasone
• antiarrhythimics e.g., mexiletine and phenytoin
• muscarinic antagonists e.g., tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;
• vanilloid receptor agonists e.g., resinferatoxin
• antagonists e.g., capsazepine
• sedatives e.g., glutethimide, meprobamate, methaqualone, and
• anxiolytics such as benzodiazepines
• antidepressants such as mirtazapine
• topical agents e.g., lidocaine, capsacin and resiniferotoxin
• muscle relaxants such as benzodiazepines, baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol and orphrenadine;
• “combination” refers to any mixture or permutation of one or more compounds of the invention and one or more other compounds of the invention or one or more additional therapeutic agent. Unless the context makes clear otherwise, “combination” may include simultaneous or sequentially delivery of a compound of the invention with one or more therapeutic agents. Unless the context makes clear otherwise, “combination” may include dosage forms of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, “combination” may include routes of administration of a compound of the invention with another therapeutic agent. Unless the context makes clear otherwise, “combination” may include formulations of a compound of the invention with another therapeutic agent. Dosage forms, routes of administration and pharmaceutical compositions include, but are not limited to, those described herein.
• kits that contain a pharmaceutical composition which includes one or more compounds of the invention.
• the kit also includes instructions for the use of the pharmaceutical composition for inhibiting the activity of voltage-gated sodium channels, preferably Na 1.6, for the treatment of epilepsy, as well as other utilities as disclosed herein.
• a commercial package will contain one or more unit doses of the pharmaceutical composition.
• such a unit dose may be an amount sufficient for the preparation of an intravenous injection.
• compounds which are light and/or air sensitive may require special packaging and/or formulation.
• packaging may be used which is opaque to light, and/or sealed from contact with ambient air, and/or formulated with suitable coatings or excipients.
• Transformations 2 nd edition (Wiley, 1999) can be effected by methods known to one skilled in the art.
• starting components may be obtained from sources such as Sigma Aldrich, Combi-Blocks, Oakwood Chemicals, Inc., Maybridge, Matrix
• Suitable protecting groups include trialkylsilyl or diarylalkylsilyl (e.g., f-butyldimethylsilyl, f-butyldiphenylsilyl or
• Suitable protecting groups for amino include f-butoxycarbonyl, benzyloxycarbonyl, trimethylsilylethoxymethyl and the like.
• Suitable protecting groups for mercapto include -C(0)-R" (where R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like.
• Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein.
• the protecting group may also be a polymer resin such as a Wang resin or a 2-chlorotrityl- chloride resin.
• the compounds of formula (I) may contain at least one asymmetric carbon atom and thus can exist as racemates, enantiomers and/or diastereoisomers. Specific enantiomers or diastereoisomers may be prepared by utilizing the appropriate chiral starting material. Alternatively, diastereoisomeric mixtures or racemic mixtures of compounds of formula (I) may be resolved into their respective enantiomers or diastereoisomers. Methods for resolution of diastereoisomeric mixtures or racemic mixtures of the compounds of formula (I), as described herein, or intermediates prepared herein, are well known in the art (e.g., E.L. Eliel and S.H. Wien, in
• Suitable processes such as crystallization (e.g., preferential crystallization, preferential crystallization in the presence of additives), asymmetric transformation of racemates, chemical separation (e.g., formation and separation of diastereomers such as diastereomeric salt mixtures or the use of other resolving agents; separation via complexes and inclusion compounds), kinetic resolution (e.g., with titanium tartrate catalyst), enzymatic resolution (e.g., lipase mediated) and chromatographic separation (e.g., HPLC with chiral stationary phase and/or with simulated moving bed technology, or supercritical fluid chromatography and related techniques) are some of the examples that may be applied (see e.g., T.J. Ward, Analytical Chemistry, 2002, 2863-2872).
• Compounds of formula (la) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 1 , R 3a and R 3b are each hydrogen, and R 7 is azabicyclo[2.2.1]heptanylmethyl, and r, R 1 , R 2 , R 5 and R 6 are each as defined in the Summary of the Invention and can be prepared by the method disclosed below in Reaction Scheme 1 wherein n is 1 to 6, each X is independently fluoro, chloro or bromo, R 4a is bromo, R 4b is fluoro, R 8 is alkyl and DPPA is diphenyl phosphoryl azide:
• a compound of formula (A) is first treated with azabicyclo[2.2.1]heptane under standard reaction conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as, but not limited to, potassium carbonate, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (B).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as, but not limited to, potassium carbonate
• the compound of formula (B) is then treated under standard catalytic hydrogenation conditions, such as the use of Raney-Ni in the presence of ammonium hydroxide, to afford the compound of formula (C).
• a compound of formula (D) is treated with an appropriate azide, such as diphenyl phosphoryl azide and a compound of formula (E) under standard Schmidt rearrangement conditions to afford a compound of formula (F).
• an appropriate azide such as diphenyl phosphoryl azide and a compound of formula (E) under standard Schmidt rearrangement conditions to afford a compound of formula (F).
• a compound of formula (G) is treated with an excess amount of compound of formula (H) under standard arene sulfonylation conditions to afford a compound of formula (J).
• the compound of formula (F) is then treated with a compound of formula
• the compound of formula (K) is then treated with a compound of formula (C) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (L).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,/ ⁇ /-diisopropylethylamine
• R 2 and R 5 are each as defined in the Summary of the Invention and can be prepared by the method disclosed below in Reaction Scheme 2 wherein each X is independently fluoro, chloro or bromo, R 6a is halo and R 8 is alkyl:
• a compound of formula (Ja) is treated with a compound of formula (F) to afford a compound of formula (Ka) in a similar manner as described above in Reaction Scheme 1 for the preparation of compound of formula (K) from a compound of formula (J) and a compound of formula (F).
• a compound of formula (N) is treated under standard arene formylation conditions to form the aldehyde compound of formula (O), which is then treated under standard nucleophilic aromatic substitution conditions to afford a compound of formula
• the compound of formula (R) is then treated under standard oxime reduction conditions to afford a compound of formula (S), which is then treated with a compound of formula (Ka) under standard nucleophilic aromatic substitution reaction conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (T).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,/ ⁇ /-diisopropylethylamine
• a compound of formula (P) where R 8 is methyl is treated under standard demethylation conditions, such as, but not limited to, treatment with boron tribromide, to afford the corresponding hydroxy compound, which is then treated with an alkyl halide under standard Williamson ether synthesis conditions to afford the corresponding alkoxy compound, which is then treated under the same conditions as described above from the preparation of a compound of formula (Q) to afford a compound of formula (lb).
• standard demethylation conditions such as, but not limited to, treatment with boron tribromide
• R 5 and R 6 are each as defined in the Summary of the Invention and can be prepared by the method disclosed below in Reaction Scheme 3 wherein n is 1 to 6, each X is independently fluoro, chloro or bromo, R 4d is alkyl, R 4c is chloro or fluoro and R 8 is alkyl:
• a compound of formula (F) is treated with a compound of formula (Ja) under standard carbamate sulfonylation conditions to afford a compound of formula (Kb).
• the compound of formula (Kb) is then treated with a compound of formula (C) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,A/-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (La), which is then treated under standard nitrogen deprotection conditions to afford a compound of formula (lc).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,A/-diisopropylethylamine
• compounds of formula (La) are reacted with a boronic acid derivative, such as, but not limited to, R 4d -B(OH) 2 , under standard Suzuki-Miyaura cross coupling conditions, such as, but not limited to, the use of a solvent such as, but not limited to, 1 ,4-dioxane, in the presence of a base, such as, but not limited to, potassium phosphate tribasic, and in the presence of a palladium catalyst composed of, for example, but not limited to, tefra/c/s(triphenylphosphine)palladium(0) or palladium(ll) acetate and tricyclohexylphosphine tetrafluoroborate, at a temperature of between about ambient temperature and 150 °C, for about 30 minutes to 16 hours to form a product, which is then deprotected under standard nitrogen deprotection conditions to afford a compound of formula (If).
• a boronic acid derivative such as, but
• compounds of formula (La) are treated under standard nitrogen deprotection conditions to afford a compound of formual (Ig).
• Compounds of formula (Id) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 2, R 3a and R 3b are each hydrogen, R 7 is azabicyclo[2.2.1]heptanylmethyl, and r, R 1 , R 2 , R 5 and R 6 are each as defined in the Summary of the Invention and can be prepared by the method disclosed below in
• Reaction Scheme 3 wherein n is 1 to 6, each X is fluoro, chloro or bromo, R 4d is alkyl, R 4b is fluoro and Pg 1 is a nitrogen-protecting group, such as 4-methoxybenzyl or 2- (tri m ethy I s i I y I ) eth oxy :
• a compound of formula R 2 -NH 2 which is commercially available or which can be prepared by methods known to one skilled in the art, is treated with a compound of formula (Jc) under standard sulfonamide formation conditions to afford a compound of formula (U).
• the compound of formula (V) is then treated with a compound of formula (C) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (W).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,/ ⁇ /-diisopropylethylamine
• the compound of formula (W) is then reacted with a boronic acid derivative such as, but not limited to, R 4d -B(OH) 2 , under standard Suzuki-Miyaura cross coupling conditions, such as, but not limited to, the use of a solvent, such as, but not limited to, 1 ,4-dioxane, in the presence of a base, such as, but not limited to, potassium phosphate tribasic, and in the presence of a palladium catalyst composed of, for example, but not limited to, tetrakis(triphenylphosphine)palladium(0) or palladium(ll) acetate and tricyclohexylphosphine tetrafluoroborate, at a temperature of between about ambient temperature and 150 °C, for about 30 minutes to 16 hours to generate a compound of formula (X), which is deprotected under standard nitrogen deprotection conditions to afford a compound of formula (Id).
• a boronic acid derivative such as
• Compounds of formula (le) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 1 , R 3a and R 3b are each hydrogen, one R 4 is alkyl and the other R 4 is halo, R 7 is azabicyclo[2.2.1]heptanylmethyl, and r, R 1 , R 2 , R 5 and R 6 are each as defined in the Summary of the Invention and can be prepared by the method disclosed below in Reaction Scheme 5 wherein n is 1 to 6, X is fluoro, chloro or bromo, R 4a is bromo, R 4d is alkyl, and R 8 is alkyl:
• a compound of formula (F) is first treated under standard carbamate sulfonylation conditions to afford a compound of formula (Kc), which is then treated with a compound of formula (C) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the presence of a base, such, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/./V-diisopropylethylamine, at ambient temperature for about 1 to 20 hours to afford a compound of formula (Lb).
• a base such as A/./V-diisopropylethylamine
• the compound of formula (Lb) is then reacted with a boronic acid derivative such as, but not limited to, R 4d -B(OH) 2 , under standard Suzuki-Miyaura cross coupling conditions, such as, but not limited to, the use of a solvent, such as, but not limited to, 1 ,4-dioxane, in the presence of a base, such as, but not limited to, potassium phosphate tribasic, and in the presence of a palladium catalyst composed of, for example, but not limited to, tetrakis(triphenylphosphine)palladium(0) or palladium(ll) acetate and tricyclohexylphosphine tetrafluoroborate, at a temperature of between about ambient temperature and 150 °C, for about 30 minutes to 16 hours to generate a compound of formula (Lc), which is deprotected under standard nitrogen deprotection conditions to afford a compound of formula (le).
• a boronic acid derivative such
• a compound of formula (Va) is first treated with a compound of formula (C) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as potassium carbonate, to afford a compound of formula (Wa), which is then deprotected under standard nitrogen deprotection conditions to afford a compound of formula (la).
• standard nucleophilic aromatic substitution conditions such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide
• a base such as potassium carbonate
• Compounds of formula (Ih) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 1 , R 3a and R 3b are each hydrogen, and R 7 is azabicyclo[2.2.1]heptanylmethyl and r, R 1 , R 2 , R 5 and R 6 are each as defined in the Summary of the Invention and are prepared as described below in Reaction Scheme 7 wherein m is 0 to 5, each X is independently fluoro, chloro or bromo, R 4b is fluoro and R 9 is hydrogen or methyl, and Pg 1 is a nitrogen-protecting group s such as
• Compounds of formula (Y) are commercially available or can be prepared by methods known to one skilled in the art.
• Compounds of formulae (C) and (Va) are prepared by methods described herein or by methods known to one skilled in the art.
• a compound of formula (Y) is first treated with a brominating agent under standard Appel reaction conditions to afford a compound of formula (Z), which is then treated with azabicyclo[2.2.1]heptane under standard reaction conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as, but not limited to, potassium carbonate, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (AA).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as, but not limited to, potassium carbonate
• the compound of formula (AA) is then treated under standard metal-halogen exchange/formylation/oxime formation conditions to afford a compound of formula (BB), which is then treated under standard oxime reduction conditions to afford a compound of formula (Ca).
• the compound of formula (Ca) is then treated with a compound of formula (Va) under standard nucleophilic aromatic substitution conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (Wa), which is then treated under standard nitrogen deprotection conditions to afford a compound of formula (Ih).
• Compounds of formula (li) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 1 , r is 2, R 3a and R 3b are each hydrogen, and R 7 is ((methyl)(prop-2-yl)amino)methyl, and R 1 , R 2 , and R 5 are each as defined in the Summary of the Invention, and are prepared as described below in Reaction Scheme 8 wherein X is independently fluoro, chloro or bromo, R 4c is chloro or bromo, R 6a is halo and R 8 is alkyl:
• a compound of formula (S) is first treated with a compound of formula (Kb) under standard nucleophilic aromatic substitution reaction conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (CC), which is then treated under standard nitrogen-deprotection conditions to afford a compound of formula (li).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,/ ⁇ /-diisopropylethylamine
• Compounds of formula (Ij) and formula (Ik) are compounds of formula (I) as described above in the Summary of the Invention wherein q is 1 , r is 2, R 3a and R 3b are each hydrogen, and R 7 is ((methyl)(prop-2-yl)amino)methyl, and R 1 , R 2 , and R 5 are each as defined in the Summary of the Invention, and are prepared as described below in Reaction Scheme 8 wherein X is independently fluoro, chloro or bromo, R 4c is chloro or bromo, R 4d is alkyl, R 6a is halo and R 8 is alkyl:
• a compound of formula (S) is first treated with a compound of formula (Kd) under standard nucleophilic aromatic substitution reaction conditions, such as, but not limited to, the use of a polar aprotic solvent, such as, but not limited to, dimethyl sulfoxide, in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, at a temperature of between about 0 °C and 80 °C, for about 1 to 48 hours to afford a compound of formula (DD), which is then treated under standard nitrogen-deprotection conditions to afford a compound of formula (Ij).
• a polar aprotic solvent such as, but not limited to, dimethyl sulfoxide
• a base such as A/,/ ⁇ /-diisopropylethylamine
• a compound of formula (DD) is reacted with a boronic acid derivative, such as, but not limited to, R 4d -B(OH) 2 , under standard Suzuki-Miyaura cross coupling conditions, such as, but not limited to, the use of a solvent such as, but not limited to, 1 ,4-dioxane, in the presence of a base, such as, but not limited to, potassium phosphate tribasic, and in the presence of a palladium catalyst composed of, for example, but not limited to, tetrakis(triphenylphosphine)palladium(0) or palladium(ll) acetate and tricyclohexylphosphine tetrafluoroborate, at a temperature of between about ambient temperature and 150 °C, for about 30 minutes to 16 hours to afford a compound of formula (EE), which is then deprotected under standard nitrogen deprotection conditions to afford a compound of formula (Ik).
• a boronic acid derivative such
• All of the compounds described below as being prepared which may exist in free base or acid form may be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid. Salts of the compounds prepared below may be converted to their free base or acid form by standard techniques. Furthermore, all compounds of the invention which contain an acid or an ester group can be converted to the corresponding ester or acid, respectively, by methods known to one skilled in the art or by methods described herein.
• the reaction mixture was diluted with ethyl acetate (150 ml_) and saturated aqueous sodium bicarbonate (150 ml_). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 c 100 ml_). The combined organic layers were washed with water (150 ml_), brine (150 ml_), dried over magnesium sulfate, and filtered. Concentration of the filtrate in vacuo provided a residue, which was purified by column chromatography, eluting with a gradient of 0 to 10% of ethyl acetate in heptane.
• reaction mixture was quenched by addition of saturated ammonium chloride solution (80 ml_), and the aqueous layer was extracted with ethyl acetate (3 c 80 ml_). The combined organic layers were washed with brine (100 ml_), dried over magnesium sulfate, and filtered.
• Step 6 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-3-bromo-2,6-difluorophenyl)sulfonyl)(isothiazol-3- yl)carbamate
• the reaction mixture was diluted with saturated aqueous ammonium chloride solution (80 ml_), and extracted with ethyl acetate (3 x 100 ml_). The combined organic layers were washed with brine (250 ml_), dried over anhydrous magnesium sulfate, and filtered. Concentration of the filtrate in vacuo provided a residue, which was dissolved in a minimum amount of dichloromethane. To it was then added dropwise heptane until the solution became cloudy and the resulting mixture was triturated using an ultrasonication bath.
• Step 7 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-2,6-difluorophenyl)sulfonyl)(isothiazol-3-yl)carbamate
• reaction mixture was stirred at -78 °C for 30 minutes, and then quenched by addition of saturated aqueous ammonium chloride (200 ml_).
• saturated aqueous ammonium chloride 200 ml_
• the mixture was allowed to warm to ambient temperature and extracted with ethyl acetate (500 ml_).
• the combined extracts were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo.
• the reaction mixture was stirred at ambient temperature for a further 16 h, and then quenched by addition of 1 M sodium hydroxide solution (200 ml_).
• the layers were separated, and the volume of the organic phase was reduced by half in vacuo.
• the remaining organic phase was washed with 1 M sodium hydroxide solution (200 ml_), brine (200 ml_), and dried over anhydrous magnesium sulfate. Filtration and concentration of the filtrate in vacuo provided a residue, which was dissolved in ethyl acetate (400 ml_) and extracted with 3 M hydrochloric acid (100 ml_, 50 ml_, and 30 ml_).
• the combined aqueous layers were cooled to 0 °C, the pH was adjusted to pH 12 with solid sodium hydroxide, and the aqueous layer was extracted with ethyl acetate (3 c 200 ml_).
• the combined organic layers were washed with 1 M sodium hydroxide solution (100 ml_), brine (200 ml_), and dried over anhydrous magnesium sulfate.
• reaction mixture was then stirred at ambient temperature for 10 minutes, and additional 1.3 M solution of isopropylmagnesium chloride lithium chloride complex in tetrahydrofuran (53 ml_, 69 mmol) was added dropwise over the course of 45 minutes.
• the reaction mixture was stirred at ambient temperature for 30 minutes and A/,/ ⁇ /-dimethylformamide (13 ml_,
• reaction mixture was filtered through a bed of celite, and the filter cake was washed with ethyl acetate (2 c 100 ml_).
• the combined filtrate was concentrated in vacuo and the residue was dissolved in ethyl acetate (500 ml_).
• To the organic phase was added 5 M sodium hydroxide until the aqueous layer of the mixture had reached pH 12.
• the aqueous layer was extracted with ethyl acetate (2 c 200 ml_).
• the combined organic layers were washed with brine (200 mL), dried over anhydrous magnesium sulfate, and filtered.
• Step 8 Preparation of tert- butyl ((2,6-difluoro-4-((6-fluoro-2-((isopropyl(methyl)- amino)methyl)-3-methoxybenzyl)amino)phenyl)sulfonyl)(thiazol-4-yl)carbamate
• the mixture was then diluted with ethyl acetate (400 mL) and washed with saturated aqueous sodium bicarbonate (250 mL). The aqueous layer was extracted with ethyl acetate (200 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (200 mL), saturated ammonium chloride (200 mL), brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to a total volume of approximately 150 mL and cooled to 5 °C.
• Step 2 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-2,3-difluorophenyl)sulfonyl)(thiazol-4-yl)carbamate
• reaction mixture was then added dropwise to a rapidly stirring aqueous ammonium chloride solution (500 ml_) and the obtained precipitate was filtered off.
• the precipitate was dissolved in ethyl acetate (250 ml_) with washed with brine (2 c 50 ml_), dried over anhydrous sodium sulfate and filtered.
• Step 1 Preparation of te/f-butyl ((3-bromo-2,4-difluorophenyl)sulfonyl)(isoxazol-3- yl)carbamate
• reaction mixture was diluted with ethyl acetate (300 ml_) and quenched by addition of saturated aqueous ammonium chloride solution (100 ml_).
• saturated aqueous ammonium chloride solution 100 ml_
• the aqueous layer was separated and extracted with ethyl acetate (2 c 100 ml_).
• the combined organic layers were washed with brine (100 ml_), dried over anhydrous magnesium sulfate, and filtered.
• Step 2 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-3-bromo-2-fluorophenyl)sulfonyl)(isoxazol-3-yl)carbamate
• the reaction mixture was diluted with ethyl acetate (150 ml_) and aqueous ammonium chloride solution (50 ml_) and the layers were separated.
• the aqueous phase was extracted with ethyl acetate (3 x 50 ml_).
• the combined organic phases were washed with brine (3 c 30 ml_), dried over anhydrous sodium sulfate, filtered and concentrated to yield the title compound as a yellow solid (0.269 g, 41 % yield) which was used without further purification: MS (ES+) m/z 653.2 (M + 1), 655.2 (M + 1) ).
• Step 3 Preparation of 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-2-fluoro-/ ⁇ /-(isoxazol-3-yl)-3-methylbenzenesulfonamide 2 , 2 , 2-tri f I uo roacetate
• reaction mixture was stirred at ambient temperature for 12 h.
• the reaction mixture was diluted with saturated aqueous ammonium chloride (200 ml_) and extracted with ethyl acetate (3 x 1000 ml_).
• the combined organic layers were washed with brine (3 c 1000 ml_), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
• the reaction mixture was diluted with ethyl acetate (150 ml_) and aqueous ammonium chloride solution (50 ml_) and the layers were separated.
• the aqueous phase was extracted with ethyl acetate (3 c 50 ml_).
• the combined organic phases were washed with brine (3 c 30 ml_), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to yield the title compound as a yellow solid (0.338 g, 54% yield) which was used without further purification: MS (ES+) m/z 625.2 (M + 1), 627.2 (M + 1) ).
• Step 3 Preparation of 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-3-chloro-2-fluoro-/ ⁇ /-(thiazol-4-yl)benzenesulfonamide 2 , 2 , 2-tri f I uo roacetate
• terf-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7- yl)methyl)-6-fluorobenzyl)amino)-3-chloro-2-fluorophenyl)sulfonyl)(thiazol-4- yl)carbamate (0.138 g, 0.221 mmol), potassium phosphate tribasic (0.141 g, 0.663 mmol), methylboronic acid (0.106 g, 1.77 mmol), tricyclohexylphosphine
• dichloromethane (32 ml_) was added sodium triacetoxyborohydride (6.25 g, 29.6 mmol). The reaction mixture was stirred at ambient temperature for 18 h and then quenched by addition of saturated aqueous ammonium chloride solution (50 ml_). The aqueous layer was extracted with dichloromethane (3 c 50 ml_) and the combined organic layers were washed with brine (50 ml_), dried over anhydrous magnesium sulfate, and filtered.
• the reaction mixture was diluted with saturated aqueous ammonium chloride solution (20 ml_), and extracted with ethyl acetate (3 c 30 ml_). The combined organic layers were washed with water (40 ml_), brine (40 ml_), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Purification of the residue by column chromatography, eluting with a gradient of 0 to 40% of ethyl acetate (containing 10% of isopropanol and 10% of triethylamine) in hexanes, provided the title compound as a colorless solid (0.38 g,
• Step 1 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluoro-3-methoxybenzyl)amino)-2,3-difluorophenyl)sulfonyl)(thiazol-4- yl)carbamate
• Step 1 Preparation of te/f-butyl isothiazol-3-yl((2,3,4-trifluorophenyl)sulfonyl)- carbamate
• Step 2 Preparation of te/f-butyl ((4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)methyl)-6- fluorobenzyl)amino)-2,3-difluorophenyl)sulfonyl)(isothiazol-3-yl)carbamate
• the reaction mixture was diluted with saturated aqueous ammonium chloride solution (30 mL), and extracted with ethyl acetate (3 c 50 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous magnesium sulfate, and filtered. Concentration of the filtrate in vacuo and purification of the residue by column chromatography, eluting with a gradient of 0 to 40% of ethyl acetate
• reaction mixture was stirred at -10 °C for 1 h, and then poured into a stirred saturated aqueous ammonium chloride solution at 0 °C in small portions.
• the mixture was extracted with ethyl acetate (3 c 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous magnesium sulfate, and filtered.
• Step 6 Preparation of te/f-butyl ((4-((2-(1-(7-azabicyclo[2.2.1]heptan-7-yl)ethyl)-3,6- difluorobenzyl)amino)-2,6-difluorophenyl)sulfonyl)(thiazol-4-yl)carbamate
• Step 1 Preparation of te/f-butyl ((2,3-difluoro-4-((6-fluoro-2- ((isopropyl(methyl)amino)methyl)-3- methoxybenzyl)amino)phenyl)sulfonyl)(thiazol-4-yl)carbamate
• Step 1 Preparation of te/f-butyl ((5-chloro-2-fluoro-4-((6-fluoro-2- ((isopropyl(methyl)amino)methyl)-3- methoxybenzyl)amino)phenyl)sulfonyl)(thiazol-4-yl)carbamate
• Electrophysiological Assay In vitro assay
• Patch voltage clamp electrophysiology allows for the direct measurement and quantification of block of voltage-gated sodium channels (Na ⁇ ’s), and allows the determination of the time- and voltage-dependence of block which has been interpreted as differential binding to the resting, open, and inactivated states of the sodium channel (Hille, B., Journal of General Physiology (1977), 69: 497-515).
• HEK human embryonic kidney cells
• EP electrophysiology
• Na 1.1 , Na I .5 and Na I .6 cDNAs (NM_001165964 (SCN1A), NM_000335 (SCN5A) and NM_014191 (SCN8A), respectively) are stably expressed in HEK-293 cells.
• Sodium currents are measured using the patch clamp technique in the whole cell configuration using either a PatchXpress automated voltage clamp or manually using an Axopatch 200B (Axon Instruments) or Model 2400 (A-M systems) amplifier.
• the manual voltage clamp protocol is as follows: Borosilicate glass micropipettes are fire-polished to a tip diameter yielding a resistance of 2-4 Mohms in the working solutions.
• the pipette is filled with a solution comprised of: 5 mM NaCI, 10 mM CsCI, 120 mM CsF, 0.1 mM CaCI 2 , 2 mM MgCI 2 , 10 mM HEPES, 10 mM EGTA; and adjusted to pH 7.2 with CsOH.
• the external solution has the following composition:
• the membrane potential is maintained at a voltage where inactivation of the channel is complete.
• Vhold -150mV
• the 20 ms brief repolarization is long enough for compound-free channels to completely recover from fast inactivation, but the compound-bound channels recover more slowly such that negligible recovery could occur during this interval.
• the percent decrease in sodium current following wash-on of compound is taken as the percent block of sodium channels.
• This sodium influx assay employs the use of the cell permeable, sodium sensitive dye ANG2 to quantify sodium ion influx through sodium channels which are maintained in an open state by use of sodium channel modulators. This high throughput sodium influx assay allows for rapid profiling and characterization of sodium channel blockers.
• Trex HEK293 cells were stably transfected with an inducible expression vector containing the full-length cDNA coding for the desired human sodium channel a-subunit and with an expression vector containing full length cDNA coding for the b ⁇ -subunit.
• Sodium channel expressing cell lines were induced with tetracycline (1 pg/mL) and plated on 384-well PDL-coated plates at a density of 25K- 30K cells/ well in culture media (DMEM, containing 10% FBS and 1 % L-glutamine).
• Hamamatsu FDSS pCell was used to perform a 1 :1 addition of Na/K challenge buffer (140 mM NaCI, 20 mM HEPES, 1 mM CaCI 2 , 15 mM KCI, 1 mM MgCI 2 , 10 mM glucose, adjusted with Tris to pH 7.4) and simultaneously read plates at excitation wavelength of 530 nm and emission wavelength set at 558 nm. Percent inhibition of sodium ion influx was calculated for each test compound at each test concentration to determine the IC 50 values.
• Na/K challenge buffer 140 mM NaCI, 20 mM HEPES, 1 mM CaCI 2 , 15 mM KCI, 1 mM MgCI 2 , 10 mM glucose, adjusted with Tris to pH 7.4
• Percent inhibition of sodium ion influx was calculated for each test compound at each test concentration to determine the IC 50 values.
• Example numbers provided in Table 1 correspond to the Example numbers herein and "Flux” refers to the Sodium Influx Assay: TABLE 1 : Inhibition of Nav1.1 , Nav1.5, and Na ⁇ l .6
• 6Hz 6Hz psychomotor seizure assay
• MES Maximal Electroshock Seizure
• the 6Hz assay is considered a model of partial seizures observed in humans (Loscher, W. and Schmidt, D., Epilepsy Res. (1988), Vol. 2, pp 145-81 ; Barton, M.E. et al., Epilepsy Res. (2001), Vol. 47, pp. 217-27).
• the MES assay is a model for generalized tonic- clonic seizures in humans and provides an indication of a compound’s ability to prevent seizure spread when all neuronal circuits in the brain are maximally active. These seizures are highly reproducible and are electrophysiologically consistent with human seizures (Toman et ai, 1946; Piredda et ai, 1984; White et ai, 1995). Experiments can be performed with healthy animals, or with seizure prone animals that have been genetically modified to model genetic epilepsy syndromes (Piredda, S. G. et ai, J. Pharmacol. Exp. Ther. (1985), Vol. 232, pp. 741-5; Toman, J.E.
• mice can be pretreated with the test compound or with the appropriate vehicle prior to the application of the electroshock.
• the eyes of mice are first anesthetized with a topical application of Alcaine (proparacaine hydrochloride) 0.5 %, one drop in each eye 30 minutes prior to the stimulation. Seizures are then induced by placing electrodes on the eyes which deliver a transcorneal current.
• Alcaine proparacaine hydrochloride
• each mouse is challenged with the low-frequency (6 Hz, 0.3 ms pulse width) stimulation for 3 sec. delivered through corneal electrodes at several intensities (12-44 mA). Animals are manually restrained and released immediately following the stimulation and observed for the presence or absence of seizure activity.
• the 6 Hz stimulation results in a seizure characterized by a minimal clonic phase that is followed by stereotyped, automatist behaviors, including twitching of the vibrissae, and Straub-tail or by a generalized tonic clonic seizure.
• the presence, type and latency to seizure (in seconds) after the application of the current are monitored. Animals not displaying a clonic or generalized tonic clonic seizure are considered“protected”. All animals are euthanized at the end of assay. Plasma and brain samples are collected.
• each mouse is challenged with an alternating current (60 Hz, 0.4-0.6 ms pulse width) for 0.2-0.5 sec. delivered through corneal electrodes at intensities (44-55 mA).
• an alternating current 60 Hz, 0.4-0.6 ms pulse width
• the MES stimulation results in a generalized tonic seizure that can be followed by a clonic seizure, automatist behaviors and Straub-tail.
• the presence, type and latency to seizure (in seconds) after the application of the current are monitored.
• An animal is considered“protected” from MES-induced seizures upon abolition of the hindlimb tonic extensor component of the seizure.
• mice are expected to resume normal exploratory behaviour within 1 to 4 minutes. Latency to seizure is recorded with a cut-off of 1 minute after which all animals are euthanized.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (18)

Applications Claiming Priority (2)

Publications (1)

Family

ID=67138087

Family Applications (1)

Country Status (23)

Cited By (1)

Families Citing this family (5)

Citations (4)

Family Cites Families (57)

• 2019
  • 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
  • 2019-06-13 MA MA052888A patent/MA52888A/fr unknown
  • 2019-06-13 CN CN201980039029.1A patent/CN112262142B/zh active Active
  • 2019-06-13 EP EP19735024.2A patent/EP3807281A1/en active Pending
  • 2019-06-13 UA UAA202008102A patent/UA127024C2/uk unknown
  • 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/pt unknown
  • 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/en not_active Ceased
  • 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
  • 2019-06-13 CA CA3103600A patent/CA3103600A1/en active Pending
  • 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
  • 2019-06-13 PE PE2020001990A patent/PE20211389A1/es unknown
  • 2019-06-13 CR CR20200613A patent/CR20200613A/es unknown
  • 2019-06-13 JP JP2020568796A patent/JP7371029B2/ja active Active
  • 2019-06-13 EA EA202092719A patent/EA202092719A1/ru unknown
  • 2019-06-13 KR KR1020217000602A patent/KR102833674B1/ko active Active
  • 2019-06-13 IL IL278949A patent/IL278949B2/en unknown
  • 2019-06-13 MX MX2020013317A patent/MX2020013317A/es unknown
  • 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/ar unknown
• 2020
  • 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
  • 2020-12-09 CL CL2020003197A patent/CL2020003197A1/es unknown
  • 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
  • 2020-12-10 NI NI202000098A patent/NI202000098A/es unknown
  • 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/es unknown
  • 2020-12-10 SA SA520420768A patent/SA520420768B1/ar unknown
• 2023
  • 2023-08-08 JP JP2023129150A patent/JP2023138672A/ja not_active Withdrawn
• 2025
  • 2025-05-30 JP JP2025090964A patent/JP2025128218A/ja active Pending

Patent Citations (5)

Non-Patent Citations (56)

Also Published As

Similar Documents

Legal Events